CHF80.00
0.50% yesterday
SIX Swiss Exchange, May 28, 05:30 pm CET
ISIN
CH0386200239
Symbol
MED
Sector

Medartis Target price 2025 - Analyst rating & recommendation

Medartis Classifications & Recommendation:

Buy
80%
Hold
20%

Medartis Price Target

Target Price CHF93.60
Price CHF80.00
Potential
Number of Estimates 4
4 Analysts have issued a price target Medartis 2026 . The average Medartis target price is CHF93.60. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 4 Analysts recommend Medartis to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medartis stock has an average upside potential 2026 of . Most analysts recommend the Medartis stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 224.83 259.03
6.05% 15.21%
EBITDA Margin 18.76% 17.74%
52.45% 5.44%
Net Margin 1.57% 6.33%
436.89% 303.17%

4 Analysts have issued a sales forecast Medartis 2025 . The average Medartis sales estimate is

CHF259m
Unlock
. This is
15.21% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF271m 20.54%
Unlock
, the lowest is
CHF250m 11.28%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF225m 6.05%
2025
CHF259m 15.21%
Unlock
2026
CHF299m 15.41%
Unlock
2027
CHF343m 14.73%
Unlock

4 Analysts have issued an Medartis EBITDA forecast 2025. The average Medartis EBITDA estimate is

CHF45.9m
Unlock
. This is
55.58% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF47.4m 60.57%
Unlock
, the lowest is
CHF43.8m 48.16%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF42.2m 61.67%
2025
CHF45.9m 8.92%
Unlock
2026
CHF55.3m 20.43%
Unlock
2027
CHF65.6m 18.56%
Unlock

EBITDA Margin

2024 18.76% 52.45%
2025
17.74% 5.44%
Unlock
2026
18.51% 4.34%
Unlock
2027
19.13% 3.35%
Unlock

4 Medartis Analysts have issued a net profit forecast 2025. The average Medartis net profit estimate is

CHF16.4m
Unlock
. This is
364.31% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF21.2m 500.57%
Unlock
, the lowest is
CHF13.1m 272.24%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF3.5m 469.35%
2025
CHF16.4m 364.31%
Unlock
2026
CHF22.8m 39.05%
Unlock
2027
CHF28.2m 23.74%
Unlock

Net Margin

2024 1.57% 436.89%
2025
6.33% 303.17%
Unlock
2026
7.62% 20.38%
Unlock
2027
8.22% 7.87%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 0.29 1.32
480.00% 355.17%
P/E 60.51
EV/Sales 4.19

4 Analysts have issued a Medartis forecast for earnings per share. The average Medartis EPS is

CHF1.32
Unlock
. This is
325.81% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF1.71 451.61%
Unlock
, the lowest is
CHF1.06 241.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF0.29 480.00%
2025
CHF1.32 355.17%
Unlock
2026
CHF1.84 39.39%
Unlock
2027
CHF2.27 23.37%
Unlock

P/E ratio

Current 258.06 83.11%
2025
60.51 76.55%
Unlock
2026
43.54 28.04%
Unlock
2027
35.17 19.22%
Unlock

Based on analysts' sales estimates for 2025, the Medartis stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.83 3.59%
2025
4.19 13.29%
Unlock
2026
3.63 13.36%
Unlock
2027
3.16 12.83%
Unlock

P/S ratio

Current 4.86 0.63%
2025
4.22 13.20%
Unlock
2026
3.66 13.35%
Unlock
2027
3.19 12.84%
Unlock

Current Medartis Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
STIFEL EUROPE
Locked
Locked
Locked Mar 23 2025
RESEARCH PARTNERS AG
Locked
Locked
Locked Mar 19 2025
BRYAN GARNIER
Locked
Locked
Locked Mar 17 2025
RESEARCH PARTNERS AG
Locked
Locked
Locked Aug 20 2024
BRYAN GARNIER
Locked
Locked
Locked Aug 19 2024
STIFEL EUROPE
Locked
Locked
Locked Aug 19 2024
Analyst Rating Date
Locked
STIFEL EUROPE:
Locked
Locked
Mar 23 2025
Locked
RESEARCH PARTNERS AG:
Locked
Locked
Mar 19 2025
Locked
BRYAN GARNIER:
Locked
Locked
Mar 17 2025
Locked
RESEARCH PARTNERS AG:
Locked
Locked
Aug 20 2024
Locked
BRYAN GARNIER:
Locked
Locked
Aug 19 2024
Locked
STIFEL EUROPE:
Locked
Locked
Aug 19 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today